Participated · Series C · Jul 2024

Adona Medical is a pre-clinical medical technology company focused on solutions for advanced heart failure. It is developing an adjustable interatrial shunt with integrated bi-atrial pressure monitoring alongside remote patient monitoring components as part of a heart failure management platform. The platform is investigational and not approved for use in the U.S. or elsewhere. The company plans to use newly raised capital to further product development and to initiate clinical use of the adjustable interatrial shunt and monitoring capabilities. Adona Medical raised $33.5M in a Series C financing to support those plans. The company is a Los Gatos, CA–based Shifamed portfolio company led by CEO Brian Fahey. Adona Medical is a pre-clinical stage medical technology company developing a next-generation heart failure management platform. The company is led by CEO Brian Fahey and is a privately held portfolio company of Shifamed LLC. Its core work focuses on next-generation solutions for patients with advanced heart failure. Adona intends to use new funding to complete product development and to support further evaluation of its platform. The article does not provide operating metrics such as revenue or user counts. Adona is based in Campbell, California. Adona Medical focuses on advanced interventional approaches for heart failure. The company is a privately held portfolio company of medical innovation hub Shifamed LLC and is based in Campbell, CA. It raised $2.5M in seed financing to advance product development and expand its intellectual property portfolio. The round was funded exclusively by select Shifamed accredited angel investors. Leadership includes newly appointed CEO Brian Fahey and Chairman Amr Salahieh. Fahey joins Adona with over 15 years of medtech leadership and product development experience.

Participated · Series B · May 2024

Brixton Biosciences is a clinical-stage life sciences company developing Neural Ice, an injectable, drug-free pain management technology intended to provide long-lasting relief from chronic and post-operative pain. The company is refining Neural Ice and intends to accelerate its clinical application, expanding development beyond its initial study focused on chronic knee pain. Neural Ice is positioned as a non-pharmacological alternative aimed at reducing reliance on opioids and addressing aspects of the opioid crisis. Brixton recently received first-year funding of a $2 million grant (R44AR084998) from the NIH HEAL Initiative to support its development work. The award is intended to enable further development and clinical advancement of Neural Ice across additional indications. Sameer Sabir, CEO and co-founder, characterized the grant as a significant step toward bringing safer, non-addictive pain options to a broad array of patients. Brixton Biosciences is a Cambridge, MA-based clinical-stage life sciences company spun out of Massachusetts General Brigham and led by CEO Sameer Sabir. Its lead therapeutic approach, Neural Ice™, is a single, safe, drug-free injectable designed to provide locally targeted, non-addictive, and comparatively long-lasting pain relief. The company plans to use new capital to initiate pivotal clinical studies in both chronic and acute pain indications. Specifically, Brixton will pursue two pivotal studies to treat knee pain associated with osteoarthritis and pain from knee replacement surgery. Management says the firm intends to expand the Neural Ice platform beyond the knee to multiple pain indications with an ultra-long acting injectable nerve block. The company recently added Dr. Michael Fishman as Chief Medical Officer and appointed Reggie Groves to its board to support clinical and commercial efforts.

Participated · Equity · Aug 2023

Instylla develops next-generation liquid embolics for peripheral vascular embolotherapy and interventional oncology, with its first product Embrace HES designed for controlled, complete, and persistent embolization. The company is led by CEO Amar Sawhney and was founded in 2017 by Incept LLC. Instylla’s HES Hypervascular Tumor Pivotal Study is enrolling patients in the US and Canada to evaluate the Hydrogel Embolic System versus standard of care, and the HALT Study is enrolling to study Embrace HES for embolization of arterial bleeding. The company intends to use the proceeds from the recent financing to support ongoing prospective clinical trials and early commercialization. Instylla is based in Bedford, MA. Instylla develops the Hydrogel Embolic System (HES™), a water‑based liquid injected via standard catheters that fills target vessels and solidifies into a soft, occlusive, absorbable hydrogel causing immediate and persistent flow stasis. The company is led by CEO Amar Sawhney and was founded by Incept LLC in 2017. Instylla recently closed a $25.4M Series B financing to fund its clinical and regulatory plans. Management intends to use the proceeds to conduct several prospective clinical trials, including a pivotal trial in the United States, in preparation for market entry. The HES is not approved for sale in the United States. The financing also includes board additions as part of the round.

Led · Series A · May 2023

Sealonix is a Bedford, MA-based biomaterials company founded in January 2023 by Amar Sawhney that is developing next-generation hemostatic sealants for surgical use. Its initial product, the PramStat patch, is designed to provide rapid hemostasis in abdominopelvic and orthopedic procedures and to bioabsorb within a week after implantation. The company leverages biomaterials expertise to create surgical sealants intended for rapid bleeding control. Sealonix intends to use the funds from its recent financing to grow its development team and execute clinical trials. Founder Amar Sawhney has previously founded Confluent Surgical, Ocular Therapeutix, Augmenix, Instylla, and Rejoni.

Participated · Equity · Feb 2015

Altiostar provides open virtualized RAN (Open vRAN) software ready for 5G that supports open interfaces and separates hardware from software. Its solution runs on x86 COTS servers and supports macro and small cells for indoor and outdoor deployments. The platform includes interference management, carrier aggregation and dual reception to improve network efficiency and user experience. Operators can add intelligence, rapidly adapt software for different services, automate operations and scale networks quickly. Altiostar has tested its virtualized RAN with commercial traffic in collaboration with multiple operators and was selected by the Telco Infra Project as a leading platform for Latin America. Through its partnership with Telefónica, Altiostar aims to accelerate adoption of open, cloud‑native RAN architectures and help build an open multi‑vendor ecosystem. Altiostar provides a 5G-ready virtualized RAN software solution that supports open interfaces and disaggregates hardware from software to enable open multi-vendor, web-scale networks. Its platform supports macro and small cells for indoor and outdoor deployments and includes interference management, carrier aggregation and dual reception to improve network efficiency and user quality of experience. Operators can add intelligence, adapt the software for different services and automate operations to scale the network. Led by president and CEO Ashraf M. Dahod, the company is based in Tewksbury, MA. In August 2019 Altiostar closed a $114M Series C financing. The company intends to use the funds to expand its solution. Altiostar Networks develops networking technology aimed at improving LTE networks and emerged from stealth in November. The company is led by CEO Ashraf Dahod, who previously founded Starent Networks. Altiostar is based in Tewksbury, Massachusetts. It has disclosed multiple financings, including a $50 million raise announced in January and a $20 million addition to that latest round. According to SEC filings, the firm has now raised $140 million in equity funding since 2012. Investors have included Cisco Systems, Excelestar Ventures and the company’s founders. The company’s public disclosures to the SEC have been the source of its reported fundraising totals. Altiostar is building an array of solutions for the mobile broadband industry. The company says its vision is to enhance the communications experience and reduce the cost of technology. It describes a highly experienced team working on innovative ideas and is recruiting people with wireless broadband technology experience. Altiostar filed with the Securities and Exchange Commission reporting a $10.5 million raise in its second round of venture capital. The filing notes four separate investors participated in the offering.